Showing results (111-120 of 135) with videos related to
Sort By:
Pageof 14
Epilepsy & Behavior : E&B|August 6, 2023
Medication self-management in predominantly African American and Caribbean American people with epilepsy: The role of medication beliefs and epilepsy knowledgeCara L Crook, Seth A Margolis, Allyson Goldstein, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 11, 2020
Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic TargetsRenata Ferrarotto, Yoshitsugu Mitani, Daniel J McGrail, et al.Neuropsychology|May 19, 2022
The complementary utility of cognitive testing and the medication management ability assessment in older adultsEmily S Hallowell, Kelli L Sullivan, Jennifer D Davis, et al.Neuropsychology|May 11, 2026
Subjective and objective cognition in early-stage, treatment-naïve Parkinson's disease: Relationships with moodJacob L Varela, Seth A Margolis, Umer Akbar, et al.The Clinical Neuropsychologist|January 10, 2025
Medication adherence feedback with older adults with cognitive impairment: a mixed Methods studyKelli L Sullivan, Emily S Hallowell, Allyson Goldstein, et al.Science Advances|April 26, 2017
A murine preclinical syngeneic transplantation model for breast cancer precision medicineLorenzo Federico, Zechen Chong, Dong Zhang, et al.Frontiers in Psychology|November 16, 2020
Evaluation of Naturalistic Driving Behavior Using In-Vehicle Monitoring Technology in Preclinical and Early Alzheimer's DiseaseJennifer D Davis, Ganesh M Babulal, George D Papandonatos, et al.Journal of the American Geriatrics Society|November 1, 2012
Road test and naturalistic driving performance in healthy and cognitively impaired older adults: does environment matter?Jennifer D Davis, George D Papandonatos, Lindsay A Miller, et al.Science Translational Medicine|June 2, 2017
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancersChaoyang Sun, Yong Fang, Jun Yin, et al.Cancer Research|January 7, 2026
Defective DNA Damage Response is a Targetable Therapeutic Vulnerability in ESR1 Mutant Breast CancerSarah K Herzog, Jessica H Stevens, Guowei Gu, et al.Pageof 14